Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada Decision analytical modelling using patterns of care study data Dr Yoon-Jung Kang Abstract ID 373 Track Prevention and screening Disclosure of Interest: None Declared www.worldcancercongress.org Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada Dr Yoon-Jung Kang Optimal treatment rates for cervical cancer Optimal treatment rate = βπππ‘ππππ‘π π€ππ‘β πππ πππ π π΄ ππππππ£πππ π‘ππππ‘ππππ‘ π /π΄ππ πππ‘ππππ‘π π€ππ‘β β’β― β’β― πππ πππ π π΄β(surgery or radiotherapy); FIGO IIB-IVB (radiotherapy, chemo-radiotherapy, or chemotherapy); co-morbidities FIGO IA-IIA β’β― Data sources: the Royal Hospital for Women, Australia (year 1999-2008); CancerCare Manitoba, Canada (year 1999-2008) β’β― Model structure: recommended treatment (treatment guidelines) and other treatments (patterns of care) for FIGO sub-stage β’β― Model inputs: proportions of patients with key clinical indicators (FIGO stage distribution, performance status and etc.) Optimal treatment rates 80% 70% 70% 60% 50% 40% 30% 20% 72% 54% 28% 46% 10% 0% % cervical cancer patients % cervical cancer patients FIGO stage distribution at diagnosis (1999-β2008) 80% Higher in Canada (i.e. more advanced stage disease) 60% 50% 40% 30% 20% 10% 0% Australia Canada FIGO IA-βIIA Australia Canada FIGO IIB-βIVB Aus Can Surgery Aus Can Radiotherapy Aus Can Chemotherapy Aus Can Chemo-βradiotherapy Abstract ID 373. Disclosure of interests for presenting author: None Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada Dr Yoon-Jung Kang Radiotherapy and chemo-radiotherapy rates Chemo-βradiotherapy Radiotherapy 50% Over 40% 30% 20% 10% 0% -β10% -β20% ~20% -β30% -β40% Under (baseline) ~5% under-βu>lised Difference (observed -β optimal) Difference (observed -β optimal) 50% 40% 30% 20% 10% 0% -β10% -β20% -β30% -β40% ~44% ~15% under-βu>lised (baseline) -β50% -β50% Aus Can Overall Aus IA1 Can Aus IA2 Can Aus Can IB-βIIA Aus Can IIB-βIVA Aus Can IVB Aus Can Overall Aus IA1 Can Aus IA2 Can Aus Can Aus IB-βIIA Can IIB-βIVA Aus Can IVB Vertical lines indicate the range within which 95% of the estimates fell from the probabilistic sensitivity analysis involving a total of 3000 scenarios (i.e. 95% credible interval) Conclusion β’β― Optimal treatment rates are largely dependent on the overall stage distribution at diagnosis β’β― Radiotherapy and chemo-radiotherapy are under-utilised (especially in FIGO stage IIB-IVB disease) β’β― Assist health services planning Abstract ID 373. Disclosure of interests for presenting author: None
© Copyright 2026 Paperzz